Abnormal uterine and vaginal bleeding, unspecified. Abnormal uterine and vaginal bleeding, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 12-10 hours prior to surgery, the use of vaginal misoprostol much as 400 micrograms. Intervention 2: Control group: 12-10 hours before the operation, taking 3 tabl
Diagnosis
Intervention group: 12-10 hours prior to surgery, the use of vaginal misoprostol much as 400 micrograms
Control group: 12-10 hours before the operation, taking 3 tablets of 300 mg isoniazid vaginal
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: postmenopausal women and premenopausal women who have no history of vaginal delivery, not pregnant at the time of examination, no contraindication for receiving prostaglandin , no severe vaginal prolapse , no previous surgery on cervix or cervical incompetence. Exclusion criteria: history of vaginal delivery, pregnancy, severe vaginal prolapse, previous surgery on cervix, history of cervical insufficiency, simultaneous laparoscopy and cervical myoma.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hysteroscopy entrance without cervical dilatation. Timepoint: During surgery. Method of measurement: Hagar size. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number and percent of patients needs for cervical dilatation. Timepoint: During surgery. Method of measurement: Counting.;Maximum Hagar size interring without forces. Timepoint: During surgery. Method of measurement: Hagar. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLadan Haghighi
Iran University of Medical Science
Outcome results
None listed